Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Why Have A Benchmark explains the rationale for benchmarks in monitoring performance, setting goals, and communicating results clearly.
25,750 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
As the first required minimum distributions loom for retirees with a $250,000 balance, many face a meaningful tax bil...
Retirees on $2,500 monthly face very different realities in Mexico and Florida. Housing, insurance, and residency rul...
Tech stocks retreat as geopolitical tensions escalate and oil climbs, sending the live nasdaq composite: tech lower a...
Visa reports solid growth as it guards a $700 billion payments empire against threats from real-time rails and crypto...
June's consumer price index fell 0.4% month over month, with core prices flat. Gasoline relief helped lower the headl...
Lucid shares sank as new reports claim the EV maker is weighing drastic options, including a take-private or Chapter ...
Morgan Stanley reveals a sharper cost curve for AI data centers, suggesting only a few players can fund the next wave...
A floated plan to require annual testosterone screening for service members 30 and older could reshape military healt...
Fed policy under Warsh signals a shift toward real-time data, nudging markets toward the near-term bond curve. Morgan...
XRP’s weekly RSI dipped below 30 for the second time in its trading history, reviving talk of a possible bounce after...
Bitcoin options totaling about $1.23 billion are set to expire on Friday, July 17, 2026. Analysts expect only a muted...